The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*Yan Zhao, J Zhang, Liming Wu et al.|British Journal of Dermatology|2021Cited by 73
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical TrialYan Zhao, Jianzhong Zhang, Litao Zhang et al.|American Journal of Clinical Dermatology|2021Cited by 59
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Bo Chen, Jinyan Wang et al.|Chinese Medical Journal|2023Cited by 40
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trialYan Zhao, Jianzhong Zhang, Litao Zhang et al.|Allergy|2024Cited by 30
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical TrialYan Zhao, Jing Li, Bin Yang et al.|BioDrugs|2024Cited by 16